HQSI (Healthcare Quality Strategies, Inc)

hqsi.org

HQSI (Healthcare Quality Strategies, Inc.) provides independent medical review for private and government insurers, hospitals, third-party administrators and employers. As a URAC-certified review organization, and NAIRO member, HQSI conducts reviews in all key medical specialties always adhering to the highest ethical and professional standards.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

SLATE BIO ANNOUNCES THE LAUNCH WITH SEED FINANCING TO DEVELOP NEXT GENERATION IL-2 THERAPIES

Slate Bio | January 20, 2021

news image

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...

Read More

ANGSTROM BIO LAUNCHES AMPD™, PLATFORM FOR HIGH-ACCURACY, HIGH-FREQUENCY, LOW-COST COVID-19 AND RESPIRATORY PATHOGEN TESTING

Angstrom Bio | October 14, 2020

news image

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...

Read More

Cell and Gene Therapy

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

news image

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More

Cell and Gene Therapy, Industrial Impact

OXFORD NANOPORE TECHNOLOGIES COLLABORATES WITH UPS HEALTHCARE

Oxford Nanopore Technologies | February 17, 2023

news image

On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided ...

Read More
news image

Medical

SLATE BIO ANNOUNCES THE LAUNCH WITH SEED FINANCING TO DEVELOP NEXT GENERATION IL-2 THERAPIES

Slate Bio | January 20, 2021

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...

Read More
news image

ANGSTROM BIO LAUNCHES AMPD™, PLATFORM FOR HIGH-ACCURACY, HIGH-FREQUENCY, LOW-COST COVID-19 AND RESPIRATORY PATHOGEN TESTING

Angstrom Bio | October 14, 2020

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...

Read More
news image

Cell and Gene Therapy

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More
news image

Cell and Gene Therapy, Industrial Impact

OXFORD NANOPORE TECHNOLOGIES COLLABORATES WITH UPS HEALTHCARE

Oxford Nanopore Technologies | February 17, 2023

On February 16, 2023, Oxford Nanopore Technologies announced that it will be furthering its collaboration with UPS Healthcare to expedite the distribution of its Oxford Nanopore DNA/RNA sequencing products and consumables throughout the Asia Pacific region. The collaborative effort will strengthen the supply chain for Oxford Nanopore's portable, real-time DNA sequencing devices in key markets across Asia. By leveraging the specialized healthcare logistics solutions provided ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us